SignalHF vs PeraMobile and PeraWatch
AI Verdict
Choose SignalHF if…
Choose SignalHF if your primary objective is to proactively prevent heart failure hospitalizations specifically in patients with cardiac implantable electronic devices (CIEDs). This FDA-cleared AI algorithm excels at analyzing manufacturer-agnostic CIED data to provide 30-day predictive alerts, enabling highly targeted and personalized interventions for this high-risk population.
View SignalHF →Choose PeraMobile and PeraWatch if…
Choose PeraMobile and PeraWatch if you require a comprehensive, system-wide solution for real-time patient acuity scoring and general deterioration prediction across your entire patient population. This platform, powered by the Rothman Index and integrated with EHRs, is ideal for enabling mobile clinicians and virtual surveillance teams to identify at-risk patients sooner across various conditions.
View PeraMobile and PeraWatch →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | SignalHF | PeraMobile and PeraWatch |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | SaaS | Software-only, integrated with EHRs, web-based access, mobile application, on user-provided hardware. |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PeraMobile and PeraWatchPeraMobile and PeraWatch (Tool B) offer explicit features like mobile access for on-the-go clinicians and visual, color-coded dashboards for real-time patient condition trends, which enhance immediate usability and situational awareness. While SignalHF (Tool A) focuses on reducing alert fatigue and unifying data, the direct mobile and visual presentation of patient acuity in Tool B provides a more tangible advantage in diverse clinical settings.
Clinical Value
PeraMobile and PeraWatchPeraHealth's Rothman Index (Tool B) offers a broader, disease-agnostic measure of patient acuity with extensive validation across various patient populations and outcomes, including a 30% reduction in in-hospital mortality and decreased unplanned ICU transfers. While SignalHF (Tool A) demonstrates strong clinical value in its specialized area of heart failure prediction, the wider applicability and proven impact of the Rothman Index across general patient deterioration give Tool B an advantage in overall clinical utility.
Pricing & Value
SignalHFWhile both tools have opaque pricing, SignalHF (Tool A) provides specific evidence of substantial healthcare cost reductions and a 'negative incremental cost-effectiveness ratio of -u20ac103 per day of life outside of hospital,' indicating clear economic benefits. PeraHealth (Tool B) also claims cost reductions and improved outcomes, but the detailed cost-effectiveness metrics provided for SignalHF offer a more concrete demonstration of value.
Enterprise Readiness
PeraMobile and PeraWatchPeraHealth (Tool B), now part of Spacelabs Healthcare, demonstrates strong enterprise readiness through its explicit integration with major EHR vendors, mobile application capabilities, and a proven track record with over 80 leading hospitals. Its acquisition by Spacelabs Healthcare further solidifies its position as a robust, scalable enterprise solution. While SignalHF (Tool A) offers SaaS deployment and manufacturer-agnostic CIED compatibility, Tool B's broader integration and corporate backing provide a more comprehensive enterprise solution.
Innovation
SignalHFSignalHF (Tool A) demonstrates higher innovation by being the 'first pacemaker compatible heart failure algorithm on the market' and leveraging advanced AI to predict heart failure hospitalizations within 30 days from diverse CIED data. Its development involved access to a large health data hub and includes other AI-powered features like an ILR ECG Analyzer to reduce false positives, showcasing cutting-edge application of AI in cardiac remote monitoring. While the Rothman Index (Tool B) was innovative at its inception, SignalHF's specialized and recent AI advancements provide a stronger claim to current innovation.
Support & Docs
PeraMobile and PeraWatchWhile neither tool provides explicit public details on support and documentation in the structured facts or easily discoverable web searches, PeraHealth's acquisition by Spacelabs Healthcare, a larger and more established medical device company, suggests a more robust and structured support and documentation framework. Implicity (Tool A) mentions support for research activities, but lacks clear indications of general product support for its users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | PeraMobile and PeraWatch |
|---|---|---|
| Name | SignalHF | PeraMobile and PeraWatch |
| Company | Implicity | PeraHealth (acquired by Spacelabs Healthcare) |
| Description | FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. | Predictive analytics solutions powered by the FDA-cleared Rothman Index, to help healthcare providers identify at-risk patients sooner for earlier intervention, improve quality, and reduce costs. |
| Key Functionality | Predicts heart failure hospitalizations within 30 days; analyzes physiological data, demographics, lead measurements, episodes, and therapies from CIEDs. | Real-time patient acuity scoring (Rothman Index); predictive analytics for patient deterioration; system-wide virtual surveillance. |
| Specialties | Cardiology | Critical Care, Emergency Medicine, Hospital Medicine |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and PeraMobile and PeraWatch.